Compare APLD & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APLD | HALO |
|---|---|---|
| Founded | 2001 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9B | 8.1B |
| IPO Year | 2021 | 2001 |
| Metric | APLD | HALO |
|---|---|---|
| Price | $30.05 | $77.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 11 |
| Target Price | $38.33 | ★ $78.64 |
| AVG Volume (30 Days) | ★ 15.2M | 1.8M |
| Earning Date | 04-08-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.45 | N/A |
| EPS | N/A | ★ 1.22 |
| Revenue | $144,193,000.00 | ★ $151,862,000.00 |
| Revenue This Year | $163.85 | $28.24 |
| Revenue Next Year | $64.81 | $12.56 |
| P/E Ratio | ★ N/A | $64.38 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.79 | $57.68 |
| 52 Week High | $50.73 | $82.26 |
| Indicator | APLD | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 41.03 | 58.28 |
| Support Level | $29.10 | $67.12 |
| Resistance Level | $36.86 | $82.24 |
| Average True Range (ATR) | 2.31 | 2.35 |
| MACD | -0.04 | -0.26 |
| Stochastic Oscillator | 52.25 | 49.04 |
Applied Digital Corp is a designer, developer, and operator of next-generation digital infrastructure across North America. It provides digital infrastructure solutions and cloud services to industries like High-Performance Computing (HPC) and Artificial Intelligence (AI). The company operates in the following business segments: Data Center Hosting Business and HPC Hosting Business. The majority of its revenue is generated from the Data Center Hosting Business, which operates data centers to provide energized space to crypto mining customers.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.